Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Axsome Therapeutics to $106 from $109 and keeps a Buy rating on the shares post the Q1 report. The analyst has continued confidence in Auvelity in depression.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $112 from $108 at Baird
- Axsome Therapeutics price target lowered to $125 from $127 at Citi
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics announces anticipated milestones
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
